Sign in

CIK 0001875558

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Nuvectis Pharma, Inc.

Sign in to watch
Ticker
NVCT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
862405608
Phone
+1 360-837-7232
Business address
1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
  1. 4 Open-market buy Chairman & CEO bought 260 shares at an average $15.52 ($4,035)
  2. 4 Open-market buy 10% owner bought 3,285 shares at $15.09 ($49,571)
  3. 4 Open-market buy 10% owner bought 10,000 shares at $15.36 ($153,600)
  4. 4 Open-market buy 10% owner bought 8,948 shares at $15.19 ($135,920)
  5. 4 Open-market buy 10% owner bought 3,179 shares at $15.01 ($47,717)
  6. 4 Open-market buy Chairman & CEO bought 320 shares at $14.88 ($4,762)
  7. 4 Open-market buy 10% owner bought 1,176 shares at $15.52 ($18,252)
  8. 4 Open-market buy 10% owner bought 16,760 shares at $16.46 ($275,870)
  9. 4 Open-market buy Chairman & CEO bought 750 shares at $16.50 ($12,375)
  10. 4 Open-market buy 10% owner bought 73,175 shares at $17.43 ($1,275,440)
  11. 4 Open-market buy 10% owner bought 13,090 shares at an average $17.72 ($231,964)
  12. 4 Open-market buy Chairman & CEO bought 500 shares at $17.88 ($8,940)
  13. 4 Open-market buy 10% owner bought 12,700 shares at $17.75 ($225,425)
  14. 4 Grant or award Director acquired 18,000 shares (grant or award)
  15. 4 Grant or award Director acquired 18,000 shares (grant or award)
  16. 4 Grant or award Director acquired 18,000 shares (grant or award)
  17. 4 Open-market buy 10% owner bought 32,124 shares at an average $17.71 ($568,848)
  18. 4 Open-market buy Chairman & CEO bought 350 shares at an average $17.45 ($6,108)
  19. 4 Open-market buy Chairman & CEO bought 330 shares at $17.28 ($5,702)
  20. 4 Open-market buy Chairman & CEO bought 200 shares at $17.49 ($3,498)

Page 4 of 7 · 139 filings